What is combined hepatocellular-cholangiocarcinoma?
Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare primary liver cancer that contains two kinds of cancer cells in the same tumour. Some cells resemble liver cells (hepatocytes), as in hepatocellular carcinoma (HCC). Others resemble bile duct cells (cholangiocytes), as in intrahepatic cholangiocarcinoma (iCCA).
These tumours have been described for over a century, but they are now recognised more often. An international consensus in 2018 agreed on a common name and definition, so that doctors around the world can study and treat them in the same way (Brunt et al., 2018). The diagnosis is made mainly from the appearance of the tumour under the microscope, with special stains used for support.
cHCC-CCA shares many risk factors with HCC, such as cirrhosis and chronic hepatitis B or C. On average it carries a poorer outlook than HCC, much like intrahepatic cholangiocarcinoma (Beaufrère, Calderaro and Paradis, 2021).
Surgery offers the best chance of cure. For cancer that cannot be removed, doctors use chemotherapy, targeted drugs or immunotherapy, but there is still no agreed standard treatment.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of cancer | Primary liver cancer with both liver-cell and bile-duct-cell features |
| How common | A small minority of primary liver cancers |
| Typical age | Usually 55-75 |
| Sex | More common in men |
| Main risk factors | Cirrhosis, hepatitis B or C, alcohol, fatty liver disease |
| Tumour markers | AFP, CA 19-9 or both may be raised |
| Common sites of spread | Lymph nodes, elsewhere in the liver, lungs, bone, peritoneum |
| Main treatment | Liver resection with lymph node removal; systemic therapy for advanced disease |
| Outlook | Worse than HCC; similar to intrahepatic cholangiocarcinoma |
2. How cHCC-CCA compares with other liver cancers
| Feature | Hepatocellular carcinoma | Combined HCC-CCA | Intrahepatic cholangiocarcinoma |
|---|---|---|---|
| Cell type | Liver cells | Both | Bile duct cells |
| Cirrhosis | Very common | Common | Less common |
| Raised AFP | Often | Sometimes | Rarely |
| Raised CA 19-9 | Rarely | Sometimes | Often |
| Lymph node spread | Uncommon | Common | Common |
| Liver transplant | Standard for selected patients | Controversial | Only in research settings |
3. Causes and risk factors
| Risk factor | Notes |
|---|---|
| Cirrhosis | Scarring of the liver from any cause |
| Chronic hepatitis B | A major risk factor, especially in Asia |
| Chronic hepatitis C | A major risk factor in Europe and North America |
| Alcohol | Long-term heavy drinking |
| Metabolic dysfunction-associated fatty liver disease | Linked with obesity and type 2 diabetes |
| Male sex and older age | Most patients are older men |
How does it develop?
Researchers are still debating its origin. One idea is that cHCC-CCA arises from liver stem or progenitor cells, which can develop into either liver cells or bile duct cells. Another is that an HCC or iCCA changes its features as it grows. Molecular studies show that both parts of the tumour usually come from the same original cell.
4. How does it look
On scans
| Feature | Description |
|---|---|
| Mixed pattern | Some areas behave like HCC on contrast scans, others like cholangiocarcinoma |
| Arterial enhancement | Bright areas in the arterial phase, like HCC |
| Delayed enhancement | Gradual filling in, typical of fibrous bile duct cancers |
| Capsule retraction | Pulling in of the liver surface in some cases |
| Lymph nodes | Enlarged nodes near the liver are common |
Because the scan appearance is often mixed, cHCC-CCA is easily mistaken for HCC or cholangiocarcinoma before surgery.
Under the microscope
| Feature | Description |
|---|---|
| HCC component | Sheets and trabeculae of cells resembling liver cells |
| Cholangiocarcinoma component | Glands surrounded by fibrous tissue |
| Transition zones | Areas where the two components blend |
| Intermediate cell carcinoma | A subtype with cells that have features of both types |
Special stains
| Marker | Points towards |
|---|---|
| HepPar-1, arginase-1, glypican-3 | Liver cell differentiation |
| CK7, CK19, MUC1 | Bile duct differentiation |
| Stem cell markers (such as CD56 or EpCAM) | May be present but are not required for diagnosis |
5. Symptoms
Early cHCC-CCA often causes no symptoms. Many tumours are found during surveillance scans for people with cirrhosis or chronic hepatitis.
Common symptoms
- Pain or discomfort in the upper right abdomen
- Weight loss without trying
- Loss of appetite and feeling full quickly
- Tiredness and weakness
- A lump or swelling under the right ribs
Symptoms of advanced disease or liver failure
| Symptom | Possible cause |
|---|---|
| Yellowing of the skin and eyes (jaundice) | Blocked bile ducts or liver failure |
| Swollen abdomen (ascites) | Fluid build-up from cirrhosis or tumour |
| Itching | Blocked bile flow |
| Confusion | Liver failure |
| Bone pain or cough | Spread to bone or lungs |
When to seek medical advice
See a doctor about persistent pain under the right ribs, unexplained weight loss or yellowing of the skin. People with cirrhosis or chronic hepatitis should attend regular liver surveillance, usually an ultrasound every 6 months.
Liver surveillance for people at risk
| Group | Recommended surveillance |
|---|---|
| People with cirrhosis | Ultrasound, with or without AFP, every 6 months |
| People with chronic hepatitis B | Regular checks; surveillance depending on age, ethnicity and family history |
| People treated for liver cancer | CT or MRI at intervals set by the team |
Surveillance helps find liver cancers at an earlier stage, when surgery or other curative treatments are more likely to be possible.
6. Diagnosis
| Test | Purpose |
|---|---|
| Blood tests | Liver function, blood count, clotting |
| Tumour markers | AFP and CA 19-9; both raised suggests a mixed tumour |
| Multiphase CT or MRI | Shows the tumour pattern, size, blood vessels and lymph nodes |
| Biopsy | Confirms the diagnosis, though a small sample may show only one component |
| CT chest | Checks for lung spread |
| Assessment of liver function | Child-Pugh score, which guides treatment choices |
| Molecular testing | May find targetable changes such as FGFR2 or IDH1, mainly in the bile duct component |
Many cHCC-CCAs are only diagnosed after surgery, when the whole tumour is examined.
Staging
Staging usually follows the TNM system for intrahepatic cholangiocarcinoma:
| Stage | Description |
|---|---|
| Stage I | A single tumour without blood vessel invasion |
| Stage II | Blood vessel invasion or several tumours |
| Stage III | Spread through the liver surface, to nearby organs or to lymph nodes |
| Stage IV | Spread to distant organs |
7. Treatment
Treatment is planned by a liver cancer multidisciplinary team, including hepatobiliary surgeons, hepatologists, oncologists and radiologists.
Surgery
| Option | Notes |
|---|---|
| Liver resection | Removal of the part of the liver containing the tumour |
| Lymph node dissection | Usually recommended because nodal spread is common |
| Liver transplant | Not standard; considered only in selected cases or trials |
Resection with lymph node dissection is currently the only treatment that can cure cHCC-CCA (Beaufrère, Calderaro and Paradis, 2021). It is possible when the tumour is limited and the remaining liver works well enough.
What to expect around liver surgery
| Stage | What happens |
|---|---|
| Before | Scans to measure the remaining liver; sometimes portal vein embolisation to grow the healthy side |
| Operation | Open or keyhole removal of part of the liver and nearby lymph nodes |
| After | A short stay in high-dependency care, then the ward |
| Hospital stay | Usually 5-10 days |
| Recovery | The liver regrows over several weeks; most people need 6-12 weeks to feel fully recovered |
| Results | Pathology confirms both components, margins and lymph node status |
Local treatments
| Treatment | When used |
|---|---|
| Ablation | Small tumours in people unable to have surgery |
| Chemoembolisation (TACE) | Tumours confined to the liver |
| Radioembolisation (SIRT) | Larger tumours confined to the liver |
| Stereotactic radiotherapy | Selected tumours not suitable for surgery |
These treatments are borrowed from HCC care. They may work less well against the bile duct component.
Systemic treatment
| Treatment | Evidence |
|---|---|
| Gemcitabine plus cisplatin | In 123 patients at one US centre, disease control was better with gemcitabine and a platinum drug than with gemcitabine and 5-FU (Trikalinos et al., 2018) |
| Chemotherapy versus sorafenib | In a European study of 101 patients, survival was not clearly different between chemotherapy and non-chemotherapy treatments (Pomej et al., 2023) |
| Immunotherapy | Some patients respond; durvalumab or pembrolizumab with chemotherapy is often used, following cholangiocarcinoma practice |
| Targeted drugs | For FGFR2 fusions, IDH1 mutations or other changes, when found |
| Clinical trials | Strongly encouraged |
In the European cohort, patients were mostly men (69%) with an average age of about 65. Of 7 patients given immune checkpoint inhibitors, 2 had a response (Pomej et al., 2023).
Side effects
| Treatment | Possible side effects |
|---|---|
| Liver surgery | Pain, bleeding, bile leak, temporary liver failure |
| TACE or SIRT | Pain, fever, nausea, tiredness |
| Chemotherapy | Tiredness, infection risk, nausea, low blood counts |
| Immunotherapy | Inflammation of the bowel, liver, lungs, skin or hormone glands |
| Kinase inhibitors | Hand-foot skin reaction, diarrhoea, high blood pressure |
8. Outlook (prognosis)
| Factor | Effect on outlook |
|---|---|
| Complete removal | Best chance of long-term survival |
| Lymph node spread | Worse outlook |
| Blood vessel invasion | Higher recurrence risk |
| Underlying cirrhosis | Limits treatment options |
| Advanced disease | Treatment aims to control growth and symptoms |
Overall, the outlook for cHCC-CCA is worse than for HCC and similar to intrahepatic cholangiocarcinoma (Beaufrère, Calderaro and Paradis, 2021). Recurrence after surgery is common, so close follow-up is needed.
If the cancer comes back
Recurrence is most common within the first two years after surgery, usually inside the liver. Options depend on where it appears and how well the liver works. A single recurrence may be treated with repeat surgery or ablation, while widespread disease is treated with systemic therapy. Palliative care teams help with pain, itching, appetite and emotional support at any stage, not only at the end of life.
9. Follow-up
| Follow-up | Purpose |
|---|---|
| CT or MRI every 3-6 months | Detects recurrence in the liver or elsewhere |
| AFP and CA 19-9 | Rising levels may signal recurrence |
| Liver function tests | Monitor the remaining liver |
| Hepatitis treatment | Antiviral therapy for hepatitis B or C |
| Cirrhosis care | Varices screening, nutrition and vaccination |
10. Living with combined hepatocellular-cholangiocarcinoma
- Avoid alcohol completely to protect your liver
- Take antiviral medicines as prescribed if you have hepatitis B or C
- Eat a balanced diet with enough protein; a dietitian can help if you are losing weight
- Stay active within your limits
- Check with your team before taking new medicines, including herbal remedies and painkillers
- Report jaundice, fever, confusion or swelling promptly
- Get vaccinated against hepatitis A and B, flu and pneumococcus if your team advises it
- Keep a symptom diary to share at clinic visits, noting weight, appetite and pain
- Seek support from liver cancer charities and palliative care teams when needed
11. Frequently asked questions
| Question | Answer |
|---|---|
| Is it the same as liver cancer? | It is a type of primary liver cancer with mixed features |
| Why was my diagnosis changed after surgery? | Biopsies and scans often show only one part of the tumour |
| Can I have a liver transplant? | Usually not; it is considered only in selected cases |
| Will hepatitis treatment help? | Yes, it protects the liver and may lower the risk of new tumours |
| Is it inherited? | No; it develops because of acquired liver damage and chance changes in cells |
| Should my family be tested for hepatitis? | Yes, close contacts of people with hepatitis B should be tested and vaccinated |
| Can diet help? | Good nutrition supports recovery; limit salt if you have fluid build-up |
| Are there clinical trials? | Yes; ask your team about trials for liver or biliary cancers |
12. Questions to ask your care team
- Can the tumour be removed with surgery?
- Will my lymph nodes be removed?
- How well is my liver working?
- Has the tumour been tested for FGFR2, IDH1 or other targetable changes?
- Which systemic treatment do you recommend, and why?
- How often will I have scans and blood tests after treatment?
- Am I eligible for a clinical trial?
- Can I be referred to a palliative care or symptom control team?
Resources
- Beaufrère, A., Calderaro, J. and Paradis, V. (2021) ‘Combined hepatocellular-cholangiocarcinoma: an update’, Journal of Hepatology, 74(5), pp. 1212-1224.
- Brunt, E. et al. (2018) ‘cHCC-CCA: consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentiation’, Hepatology, 68(1), pp. 113-126.
- Pomej, K. et al. (2023) ‘Clinical characteristics and outcome of patients with combined hepatocellular-cholangiocarcinoma: a European multicenter cohort’, ESMO Open, 8(1), 100783.
- Trikalinos, N.A. et al. (2018) ‘Systemic therapy for combined hepatocellular-cholangiocarcinoma: a single-institution experience’, Journal of the National Comprehensive Cancer Network, 16(10), pp. 1193-1199.
- National Cancer Institute (2026) Hepatocellular Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/liver/hp/adult-liver-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.